Search

Displaying results 5451 - 5460 of 10000 in total
  1. Drug

    Remacemide

    go.drugbank.com/drugs/DB06458
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  3. Drug

    Piboserod

    go.drugbank.com/drugs/DB04873
    Investigational

    Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

  4. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.

  5. Drug

    Masofaniten

    go.drugbank.com/drugs/DB21580
    Investigational

    Masofaniten is under investigation in clinical trial NCT06312670 (Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer). … Masofaniten has a monoisotopic molecular weight of 534.09 Da.

  6. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.

  7. Drug

    Furafylline

    go.drugbank.com/drugs/DB14029
    Experimental

    Furafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for [theophylline].

  8. Drug

    PF-06459988

    go.drugbank.com/drugs/DB14768
    Investigational

    PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).

  9. Drug

    ALT-801

    go.drugbank.com/drugs/DB15386
    Investigational

    ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).

  10. Drug

    E1v1.11

    go.drugbank.com/drugs/DB18363
    Experimental

    E1v1.11 is an antisense oligonucleotide targeting the _SMN2_ gene which is under investigation for the treatment of spinal muscular atrophy (SMA).[L48196]